3,461 Eli Lilly and Company $LLY Shares Sold by Range Financial Group LLC

Range Financial Group LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 63.8% in the third quarter, Holdings Channel reports. The institutional investor owned 1,966 shares of the company’s stock after selling 3,461 shares during the period. Range Financial Group LLC’s holdings in Eli Lilly and Company were worth $2,275,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Benchmark Financial Wealth Advisors LLC increased its stake in shares of Eli Lilly and Company by 11.0% in the third quarter. Benchmark Financial Wealth Advisors LLC now owns 1,083 shares of the company’s stock valued at $1,253,000 after buying an additional 107 shares during the period. Cushing Capital Partners LLC acquired a new position in shares of Eli Lilly and Company in the third quarter worth approximately $589,000. Physician Wealth Advisors Inc. lifted its stake in shares of Eli Lilly and Company by 5.4% in the third quarter. Physician Wealth Advisors Inc. now owns 1,080 shares of the company’s stock worth $1,249,000 after acquiring an additional 55 shares during the period. Carnegie Investment Counsel lifted its stake in shares of Eli Lilly and Company by 46.5% in the third quarter. Carnegie Investment Counsel now owns 16,281 shares of the company’s stock worth $18,839,000 after acquiring an additional 5,167 shares during the period. Finally, Pinnacle Associates Ltd. boosted its holdings in Eli Lilly and Company by 2.3% in the third quarter. Pinnacle Associates Ltd. now owns 63,439 shares of the company’s stock valued at $73,404,000 after acquiring an additional 1,396 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 2.9%

NYSE LLY opened at $1,308.21 on Friday. The stock has a market capitalization of $1.23 trillion, a P/E ratio of 43.90, a P/E/G ratio of 1.69 and a beta of 0.46. The business has a 50 day simple moving average of $1,184.78 and a 200 day simple moving average of $1,119.15. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a one year low of $806.02 and a one year high of $1,321.21.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same period in the previous year, the firm earned $6.31 earnings per share. The company’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts expect that Eli Lilly and Company will post 33.56 earnings per share for the current year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: GLP-1 leadership remains the central growth catalyst. Lilly’s Mounjaro and Zepbound franchises continue to drive explosive growth in cardiometabolic and incretin medicines, strengthening the bull case relative to more diversified peers such as Amgen and Bristol Myers Squibb. Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
• Positive Sentiment: Lilly is expanding production capacity. The company broke ground on a $5 billion Richmond, Virginia, facility as part of a more than $50 billion U.S. manufacturing build-out. The integrated site will produce active ingredients and finished medicines, including next-generation cancer treatments, and is expected to create 650 jobs. The investment could help Lilly meet demand while reducing supply constraints. Lilly breaks ground in Richmond
• Positive Sentiment: International manufacturing and logistics deals add scale. Partnerships involving Abu Dhabi-based Mubadala Bio are expected to support local packaging, logistics and contract manufacturing for Lilly’s GLP-1 medicines, improving regional distribution and market access. Lilly and Mubadala Bio sign deal
• Neutral Sentiment: Upcoming quarterly results are the next major test. Lilly is scheduled to report earnings Thursday, with investors focused on sales growth, prescription volume, pricing, supply and updated guidance. The stock’s strong run and elevated valuation increase the potential for volatility around the report. Earnings Preview: Eli Lilly Q3 Earnings Expected to Decline
• Negative Sentiment: Profitability could face pricing pressure. In the second quarter, revenue grew 48% on a 60% increase in medicine volume, but average realized prices fell 13%. This suggests Lilly must sustain exceptional volume growth to offset lower pricing, a concern ahead of its results. Eli Lilly Grew Revenue 48% While Prices Fell
• Negative Sentiment: Competition in obesity drugs is intensifying. Novo Nordisk’s CagriSema produced substantial weight-loss results, highlighting a potential competitive threat to Lilly’s GLP-1 dominance and reinforcing concerns that the stock’s premium valuation already reflects significant future growth. Obesity ETFs to Gain as Novo’s CagriSema Shows 25% Weight Loss

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Citigroup raised their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 15th. Wall Street Zen lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Saturday, October 17th. The Goldman Sachs Group reiterated a “buy” rating and set a $1,413.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday. Finally, Cantor Fitzgerald increased their price objective on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,317.93.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 in the last quarter. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.